Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02561000
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02561000
-
- Main results
- PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02561000. Randomized; quadruple masking; primary purpose prevention. Start 2016-05-27 (actual); primary completion 2019-09-17 (actual). Results posted on 2021-03-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
- Acronym
- TRIP-PCI
- Condition
- Arterial Occlusive Diseases
- Condition
- Coronary Artery Disease
- Condition
- Coronary Disease
- Condition
- Arteriosclerosis
- Condition
- Heart Diseases
- Condition
- Myocardial Ischemia
- Condition
- Vascular Diseases
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- PZ-128
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tufts Medical Center
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- RTI International
- Collaborator
- Inova Fairfax Hospital
- Collaborator
- University of Massachusetts, Worcester
Record details
- Record id
cardio:ct-nct02561000- Content hash
8fd4fca47284f89ca29fcee6f115b3d7580a7fa9ff4abd36c4731d7818b0c38a